Ardelyx
Ardelyx's revenue rose 22.1% to $407 million in fiscal 2025. Its operating margin was −10.1%, down from −8.4% a year earlier. Free cash flow was −$44 million. The diluted share count rose 2.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Ardelyx does
Ardelyx is a drug company that sells two medicines in the United States. Both use the same active ingredient, tenapanor, a pill that works in the gut and is barely absorbed into the body. Ardelyx discovered and developed it.
IBSRELA treats adults with irritable bowel syndrome with constipation. Ardelyx says about 13 million Americans have this condition. XPHOZAH lowers phosphorus in the blood of adults with chronic kidney disease who are on dialysis and have not done well on other treatments called phosphate binders. Ardelyx sells both products through its own specialty sales force aimed at stomach and intestine doctors and at kidney doctors.
Ardelyx makes money from sales of these two products. Since January 1, 2025, Medicare has paid for XPHOZAH in a different way, and Ardelyx says this hurt XPHOZAH revenue in 2025. For IBSRELA it names Linzess, Trulance and generic lubiprostone as the main competing products. It has started a late-stage trial of tenapanor in chronic idiopathic constipation, and is developing a next-generation drug of the same type. It has lost money every year since it started in 2007 and has relied on product sales, stock sales, loans and sales of future royalties to fund itself.
Its biggest risks, as it describes them
- Failing to grow sales of IBSRELA and XPHOZAH enough to produce positive cash flow.
- Needing more money, and loan terms that limit what it can do and could force repayment.
- Insurers and Medicare not covering or paying enough for its two products.
- Competition from other drugs and from companies that may bring products to market faster.
- Side effects or other problems with its medicines, and product liability lawsuits.
Income statement
Ardelyx lost money in fiscal 2025: a net loss of $62 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 117 | 124 | 184 | 250 | 265 |
| Debt incl. finance leases | 32 | 27 | 50 | 151 | 203 |
| Net debt (negative means net cash) | −84 | −97 | −134 | −99 | −62 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.4x | 0.3x | 0.3x | 0.9x | 1.2x |
| Interest coverage | −34.3x | −18.8x | −12.8x | −2.1x | −2.0x |
| Current ratio | 2.5x | 2.3x | 4.9x | 4.6x | 4.3x |
| Quick ratio | 2.5x | 1.9x | 3.9x | 3.4x | 2.9x |
Cash flow
Projections
Project Ardelyx's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Ardelyx says to expect
- Full year 2026: IBSRELA revenue
Full-year 2026 revenue guidance for IBSRELA reiterated to be between $350 and $370 million.
- Full year 2026: XPHOZAH revenue
Full-year 2026 revenue guidance for XPHOZAH reiterated to be between $110 and $120 million.
- Full year 2026: operating expenses
Full-year 2026 operating expense guidance reiterated to be below $500 million.
Insider trades
No officer, director or 10% owner of Ardelyx reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 2 of 9 | 2 of 9 |
| Rule of 40 | 66.2% | 154.3% | 11.3% |
| Altman Z'' | −5.05 | −2.17 | −2.34 |
| Accruals ratio | 9.7% | 1.6% | −4.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Fail | Fail | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 3 of 9 | 2 of 9 | 2 of 9 |
Compare
Put Ardelyx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Ardelyx | FY25 | 22.1% | −10.1% | −10.8% | −36.1% | — | 2 | |
| Innoviva | FY25 | 14.7% | 39.8% | 47.6% | 17.9% | — | 6 | Compare |
| Arcutis Biotherapeutics | FY25 | 91.3% | −3.2% | −1.7% | −16.9% | — | 4 | Compare |
| MannKind | FY25 | 22.2% | 11.1% | 3.9% | — | 3.6x | 4 | Compare |
| Travere Therapeutics | FY25 | 110.5% | −12.8% | — | — | — | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | 42 | 3 | 5 | 8 | 10 | 52 | 124 | 334 | 407 |
| Revenue growth | — | — | −93.8% | 102.6% | 43.4% | 33.4% | 416.6% | 138.6% | 168.1% | 22.1% |
| Gross profit | — | 34 | 2 | 5 | 7 | 9 | 48 | 107 | 283 | 368 |
| Research and development | 94 | 76 | 69 | 72 | 65 | 91 | 35 | 36 | 52 | 72 |
| Operating income | −113 | −65 | −91 | −91 | −91 | −154 | −64 | −63 | −28 | −41 |
| Net income | −112 | −64 | −91 | −95 | −94 | −158 | −67 | −66 | −39 | −62 |
| Diluted EPS (US$) | −2.80 | −1.36 | −1.62 | −1.47 | −1.05 | −1.52 | −0.42 | −0.30 | −0.17 | −0.26 |
| Diluted shares (millions) | 40 | 47 | 56 | 64 | 90 | 104 | 159 | 219 | 235 | 241 |
| Cash flow | ||||||||||
| Cash from operations | −92 | −65 | −70 | −76 | −81 | −153 | −70 | −90 | −45 | −42 |
| Capital expenditure | 5 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 2 |
| Free cash flow | −97 | −68 | −71 | −77 | −82 | −154 | −70 | −90 | −46 | −44 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 5 | 10 | 9 | 10 | 11 | 12 | 11 | 14 | 37 | 49 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 201 | 134 | 168 | 248 | 186 | 117 | 124 | 184 | 250 | 265 |
| Debt incl. finance leases | — | — | 52 | 50 | 51 | 32 | 27 | 50 | 151 | 203 |
| Total assets | 213 | 158 | 183 | 260 | 202 | 150 | 190 | 298 | 436 | 502 |
| Total liabilities | 20 | 19 | 68 | 73 | 76 | 67 | 92 | 131 | 262 | 335 |
| Shareholders' equity | 193 | 139 | 116 | 187 | 126 | 83 | 98 | 167 | 173 | 167 |
| Margins and ratios | ||||||||||
| Gross margin | — | 80.0% | 82.1% | 88.6% | 98.1% | 90.1% | 92.1% | 85.7% | 84.8% | 90.3% |
| Operating margin | — | −155.0% | −3,488.6% | −1,728.1% | −1,199.0% | −1,528.6% | −122.2% | −50.8% | −8.4% | −10.1% |
| Net margin | — | −153.2% | −3,502.0% | −1,797.8% | −1,245.7% | −1,566.5% | −128.8% | −53.1% | −11.7% | −15.1% |
| Free cash flow margin | — | −160.8% | −2,707.5% | −1,454.4% | −1,079.9% | −1,529.3% | −134.4% | −72.4% | −13.7% | −10.8% |
| Rule of 40 (growth + FCF margin) | — | — | −2,801.3% | −1,351.9% | −1,036.5% | −1,496.0% | 282.2% | 66.2% | 154.3% | 11.3% |
| Return on capital | — | — | — | — | — | — | — | — | −41.5% | −36.1% |
| Return on equity | −74.4% | −38.7% | −71.6% | −62.8% | −60.3% | −151.6% | −74.3% | −49.8% | −23.0% | −36.2% |
| Return on assets | −68.1% | −34.7% | −53.5% | −42.9% | −40.9% | −90.0% | −39.5% | −27.1% | −10.7% | −13.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |